Smart Nanogatekeepers for Tumor Theranostics
- 22 October 2021
- Vol. 17 (47), 2103712
- https://doi.org/10.1002/smll.202103712
Abstract
Nanoparticulate drug delivery systems (nano-DDSs) are required to reliably arrive and persistently reside at the tumor site with minimal off-target side effects for clinical theranostics. However, due to the complicated environment and high interstitial pressure in tumor tissue, they can return to the bloodstream and cause secondary side effects in normal organs. Recently, a number of nanogatekeepers have been engineered via structure-transformable/stable strategies to overcome this undesirable dilemma. The emerging structure-transformable nanogatekeepers for tumor imaging and therapy are first overviewed here, particularly for nanogatekeepers undergoing structural transformation in tumor microenvironments, cell membranes, and organelles. Thereafter, intelligent structure-stable nanogatekeepers through reversible activation and artificial individualization receptors are overviewed. Finally, the ongoing challenges and prospects of nanogatekeepers for clinical translation are briefly discussed.This publication has 157 references indexed in Scilit:
- Targeting ER stress induced apoptosis and inflammation in cancerCancer Letters, 2013
- Metabolic Glycan Imaging by Isonitrile–Tetrazine Click ChemistryChemBioChem, 2013
- Bioorthogonal Copper‐Free Click Chemistry In Vivo for Tumor‐Targeted Delivery of NanoparticlesAngewandte Chemie, 2012
- Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapyDrug Discovery Today, 2012
- The unfolded protein response: controlling cell fate decisions under ER stress and beyondNature Reviews Molecular Cell Biology, 2012
- Cancer immunotherapy comes of ageNature, 2011
- Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancerThe Lancet Oncology, 2010
- Seprase: An overview of an important matrix serine proteaseBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2008
- Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cellsProceedings of the National Academy of Sciences of the United States of America, 2007
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancerNature Reviews Drug Discovery, 2006